181 reports of this reaction
2.7% of all ERIBULIN MESYLATE reports
#8 most reported adverse reaction
INTERSTITIAL LUNG DISEASE is the #8 most commonly reported adverse reaction for ERIBULIN MESYLATE, manufactured by BSP Pharmaceuticals SpA. There are 181 FDA adverse event reports linking ERIBULIN MESYLATE to INTERSTITIAL LUNG DISEASE. This represents approximately 2.7% of all 6,741 adverse event reports for this drug.
Patients taking ERIBULIN MESYLATE who experience interstitial lung disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTERSTITIAL LUNG DISEASE is a less commonly reported adverse event for ERIBULIN MESYLATE, but still significant enough to appear in the safety profile.
In addition to interstitial lung disease, the following adverse reactions have been reported for ERIBULIN MESYLATE:
The following drugs have also been linked to interstitial lung disease in FDA adverse event reports:
INTERSTITIAL LUNG DISEASE has been reported as an adverse event in 181 FDA reports for ERIBULIN MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTERSTITIAL LUNG DISEASE accounts for approximately 2.7% of all adverse event reports for ERIBULIN MESYLATE, making it a notable side effect.
If you experience interstitial lung disease while taking ERIBULIN MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.